Compare BIO-TECHNE Corp (TECH) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Union Pacific Corporation — how do they compare? BIO-TECHNE Corp trades at $72.22 (market cap $11.24B), while Union Pacific Corporation trades at $292.1 (market cap $173.99B). The key difference: Union Pacific Corporation is far larger — about 15.5× BIO-TECHNE Corp's market cap, and Union Pacific Corporation pays the higher dividend (1.94%). Which is the better fit depends on your goals.
| TECH | UNP | |
|---|---|---|
Market Cap | $11.24B | $173.99B |
Sector | Health | Industrials |
52-Week High | $72.29 | $307.32 |
52-Week Low | $43.31 | $214.91 |
Enterprise Value | $11.32B | $203.04B |
Dividend Yield | 0.44% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.11, down 0.01% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q2 2026. The company reported Q4 2026 revenue of $321.2 million, with organic growth of 3%, and declared a $0.08 dividend. However, net income margin has declined from 25.09% in 2023 to 6.01% in 2025, and valuation ratios like P/E of 103.09 remain elevated.
The outlook is mixed: strong cash flow and institutional interest support upside, but high valuation and margin compression pose risks. Analysts are evenly split between Buy and Hold, with a consensus price target of $71.67, slightly below the current price, indicating cautious optimism amid execution challenges.
Union Pacific (UNP) trades at $292.24, down 0.3% on the day, with a neutral technical signal. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised full-year guidance. Fundamentals remain robust with a net income margin of 28.85% and ROE of 39.7%, though valuation ratios like P/E of 23.71 are elevated. Recent news highlights a 3% dividend increase and ongoing merger developments with Norfolk Southern.
The outlook is positive, driven by service-led growth, pricing power, and efficiency gains. Key opportunities include domestic intermodal expansion and margin improvement. Risks involve high fuel costs, regulatory scrutiny of the merger, and economic sensitivity. Analyst consensus is bullish with a $334.33 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
